Monitor the June 10 annual meeting outcome. If all proposals pass, expect significant dilution and a potential change in control. If they fail, the conditional director resignations would not take effect, creating uncertainty. Stock currently trades at a $43M market cap with bearish analyst consensus.
Price Chart
Executive Summary
Sensei Biotherapeutics filed additional definitive proxy materials urging stockholders to vote FOR all seven proposals at the June 10, 2026 annual meeting, including a change-of-control conversion of Series B Preferred Stock and a 24x increase in authorized shares from 12.5M to 300M. The filing follows the conditional resignation of three directors and appointment of three new directors disclosed in an April 10 8-K, all contingent on proposal approval.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for June 10, 2026 for stockholders of record April 13, 2026
- Board recommends FOR votes on all 7 proposals: director election, auditor ratification, Series B conversion approval, charter amendment to increase authorized shares from 12.5M to 300M, 2026 equity plan, 2026 ESPP, and adjournment
- Conversion of Series B Preferred would represent >20% of outstanding common and result in a change of control under Nasdaq rules
- Conditional resignations of three directors and appointments of three new directors were disclosed in an April 10 8-K, effective upon stockholder approval of the conversion and charter amendment
Financial Impact
Authorized shares would increase from 12.5 million to 300 million (24x); Series B conversion triggers change of control with undefined dilutive effect in this filing
Risk Factors
- Massive dilution if charter amendment and conversion are approved (authorized shares increase 24x)
- Change of control could lead to strategic shifts or further dilution
- Failure of proposals could create board instability and governance uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-182149 |
| Document: 0001193125-26-182149-index-headers.html | 0001193125-26-182149 |
| Document: 0001193125-26-182149-index.html | 0001193125-26-182149 |
| Document: 0001193125-26-182149.txt | 0001193125-26-182149 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 19w ago | 3 | $13.86 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 8-K | $13.04 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | EFFECT | $13.04 | awaiting T+5 | — | — |
Jun 10, 2026 19w ago | S-3/A | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 10, 2026 19w ago | 8-K | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 2, 2026 21w ago | 10-K/A | $16.10 $12.63 | ▼ −21.53% | ▼ −18.56% | — |
Jun 2, 2026 21w ago | S-3/A | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
Jun 1, 2026 21w ago | Insider Cluster | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
May 22, 2026 22w ago | DEFA14A | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
May 22, 2026 22w ago | 8-K | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers